The goal of delivering the right drug to the right cancer patient (precision medicine) requires a detailed understanding of how genomic alterations are linked to drug response. The purpose of this study is to intercept at point-of-care a large cohort of newly diagnosed mCRC patients to determine if it is possible to obtain personalized genetic information from each subject's tumor (tissue and blood) to triage treatment choices. In case of target positivity, patients will be conveyed, whenever possible, to self-standing, independent, hypothesis-driven POC trials as soon as they exhibit resistance to standard of care treatment.
Study Type
OBSERVATIONAL
Enrollment
1,000
AOU Policlinico S Orsola - Malpighi
Bologna, Italy
RECRUITINGPoliclinico S.Orsola Malpighi
Bologna, Italy
RECRUITINGFondazione del Piemonte per l'Oncologia
Candiolo, Italy
RECRUITINGIOV - Istituto Oncologico Veneto
Padova, Italy
RECRUITINGPoliclinico Universitario Campus Biomedico
Roma, Italy
RECRUITINGThoroughness to report molecular profiling
Percentage of patients with complete genotyping report produced in less than 14 days after sample acquisition.
Time frame: 14 days from sample acquisition
Frequence of genetic alteration included in the panel detected in 1000 consecutive mCRC
number of patients with detected genetic alteration included in the panel (mutations and/or copy number variations) over all recruited patients.
Time frame: 24 months from first patient in.
Percentage of complete data capture for treatment-related check-point events
Time frame: through study completion, an average of five years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.